如何开展:艰难梭菌感染的监测
本文综述了艰难梭菌感染(CDI)监测的关键组成部分并给出实践建议,包括病例定义、标准化诊断、病例来源定义及率的分母分子呈现,还需整合微生物数据以提供PCR核糖体分型和药敏信息。2017年调查显示20个欧洲国家有国家CDI监测系统,21国参与ECDC协调监测,26个欧洲国家有35个参考或中心实验室可分型。标准化监测获得的CDI发病率可作为医院和国家层面医疗质量指标。
要点
- CDI监测关键要素包括病例定义、标准化诊断、病例来源定义及率的分母分子呈现。
- 需整合微生物数据以提供流行PCR核糖体分型和对一线治疗药物的药敏信息。
- 2017年20个欧洲国家有国家CDI监测系统,21国参与ECDC协调监测。
核心结论
- 通过标准化CDI监测系统获得的CDI发病率可作为医院和国家层面医疗质量的重要指标。
研究设计与样本
- 本综述参考欧洲临床微生物学和感染病学会(ESCMID)CDI相关指南文件和欧洲疾病预防控制中心(ECDC)急性照护医院CDI监测方案定义关键组成部分。
- 总结2005-13年国际多中心CDI监测研究,并于2017年对33个欧洲国家现有CDI监测系统进行新的调查。
主要发现
- 2017年,20个欧洲国家有国家CDI监测系统,21个国家参与ECDC协调的CDI监测。
- 自2014年以来,具备艰难梭菌分型能力的中心增至26个欧洲国家的35个参考或中心实验室。
关键数值与推荐
- CDI监测的关键组成部分是适当的CDI病例定义、标准化CDI诊断、CDI病例来源定义的共识以及用明确分子和分母呈现CDI率。
- 需要整合微生物数据以提供流行PCR核糖体分型和对一线CDI治疗药物的药敏信息。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The increasing incidence of Clostridium difficile infections (CDI) in healthcare settings in Europe since 2003 has affected both patients and healthcare systems. The implementation of effective CDI surveillance is key to enable monitoring of the occurrence and spread of C. difficile in healthcare and the timely detection of outbreaks. AIMS: The aim of this review is to provide a summary of key components of effective CDI surveillance and to provide some practical recommendations. We also summarize the recent and current national CDI surveillance activities, to illustrate strengths and weaknesses of CDI surveillance in Europe. SOURCES: For the definition of key components of CDI surveillance, we consulted the current European Society of Clinical Microbiology and Infectious Diseases (ESCMID) CDI-related guidance documents and the European Centre for Disease Prevention and Control (ECDC) protocol for CDI surveillance in acute care hospitals. To summarize the recent and current national CDI surveillance activities, we discussed international multicentre CDI surveillance studies performed in 2005-13. In 2017, we also performed a new survey of existing CDI surveillance systems in 33 European countries. CONTENT: Key components for CDI surveillance are appropriate case definitions of CDI, standardized CDI diagnostics, agreement on CDI case origin definition, and the presentation of CDI rates with well-defined numerators and denominators. Incorporation of microbiological data is required to provide information on prevailing PCR ribotypes and antimicrobial susceptibility to first-line CDI treatment drugs. In 2017, 20 European countries had a national CDI surveillance system and 21 countries participated in ECDC-coordinated CDI surveillance. Since 2014, the number of centres with capacity for C. difficile typing has increased to 35 reference or central laboratories in 26 European countries. IMPLICATIONS: Incidence rates of CDI, obtained from a standardized CDI surveillance system, can be used as an important quality indicator of healthcare at hospital as well as country level.
引用
- Krutova M, Kinross P, Barbut F, et al. How to: Surveillance of Clostridium difficile infections. Clin Microbiol Infect. 2017. PMID: 29274463. doi:10.1016/j.cmi.2017.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。